Cutia Therapeutics Zukünftiges Wachstum
Future Kriterienprüfungen 2/6
Cutia Therapeutics is forecast to grow earnings and revenue by 47.2% and 41.6% per annum respectively. EPS is expected to grow by 47.2% per annum. Return on equity is forecast to be -9.6% in 3 years.
Wichtige Informationen
47.2%
Wachstumsrate der Gewinne
47.2%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 41.8% |
| Wachstumsrate der Einnahmen | 41.6% |
| Zukünftige Eigenkapitalrendite | -9.6% |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 29 Oct 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 871 | -171 | -295 | N/A | 3 |
| 12/31/2025 | 511 | -378 | -282 | -448 | 4 |
| 12/31/2024 | 275 | -476 | -546 | -492 | 4 |
| 6/30/2024 | 199 | -524 | -493 | -462 | N/A |
| 3/31/2024 | 168 | -1,244 | -465 | -422 | N/A |
| 12/31/2023 | 138 | -1,964 | -437 | -381 | N/A |
| 9/30/2023 | 91 | -1,954 | -427 | -343 | N/A |
| 6/30/2023 | 45 | -1,945 | -416 | -304 | N/A |
| 3/31/2023 | 28 | -1,250 | -394 | -270 | N/A |
| 12/31/2022 | 11 | -556 | -372 | -236 | N/A |
| 12/31/2021 | 2 | -320 | -186 | -160 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: 2487 is forecast to remain unprofitable over the next 3 years.
Ertrag vs. Markt: 2487 is forecast to remain unprofitable over the next 3 years.
Hohe Wachstumserträge: 2487 is forecast to remain unprofitable over the next 3 years.
Einnahmen vs. Markt: 2487's revenue (41.6% per year) is forecast to grow faster than the Hong Kong market (7.7% per year).
Hohe Wachstumseinnahmen: 2487's revenue (41.6% per year) is forecast to grow faster than 20% per year.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: 2487 is forecast to be unprofitable in 3 years.